Home / Pipeline / brinzolamide 1%/brimonidine 0.2% fixed combination + Placebo + travoprost 0.004% ophthalmic solution Products brinzolamide 1%/brimonidine 0.2% fixed combination + Placebo + travoprost 0.004% ophthalmic solution
brinzolamide 1%/brimonidine 0.2% fixed combination + Placebo + travoprost 0.004% ophthalmic solution Approved Completed ⚡ Active Interest: 43/100
Sep 21, 2017 → Dec 4, 2017
About brinzolamide 1%/brimonidine 0.2% fixed combination + Placebo + travoprost 0.004% ophthalmic solution brinzolamide 1%/brimonidine 0.2% fixed combination + Placebo + travoprost 0.004% ophthalmic solution is a approved stage product being developed by Novartis for Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03150160. Target conditions include Glaucoma.
What happened to similar drugs? 18 of 20 similar drugs in Glaucoma were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT03150160 Approved Completed Sep 21, 2017 Dec 4, 2017 Glaucoma
Product Company Stage Hype Score Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) Mankind Pharma Phase 3 Latanoprost plus adjunctive glaucoma medication Sight Sciences Approved SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo Skye Bioscience Phase 2 SDP-133 + Lumigan Sun Pharmaceutical Phase 3 Brinzolamide ophthalmic suspension + Azopt® Sun Pharmaceutical Phase 3 Eybelis ophthalmic solution 0.002% Santen Pharmaceutical Approved STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% Santen Pharmaceutical Phase 3 Latanoprost + tafluprost Santen Pharmaceutical Pre-clinical DE-117B Eye Drops + Latanoprost Santen Pharmaceutical Phase 3 DE-104 ophthalmic solution + DE-104 vehicle Santen Pharmaceutical Phase 2 DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5% Santen Pharmaceutical Phase 3 DE-111 ophthalmic solution Santen Pharmaceutical Phase 3 DE-111 ophthalmic solution + Timolol ophthalmic solution 0.5% + Placebo ophthalmic solution Santen Pharmaceutical Phase 3 DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicle Santen Pharmaceutical Phase 2 DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 3 STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 3 DE-117 + Latanoprost ophthalmic solution Santen Pharmaceutical Phase 3 DE-117 ophthalmic solution + Timolol ophthalmic solution Santen Pharmaceutical Phase 3 A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL Santen Pharmaceutical Phase 3 Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 2/3